These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9459338)

  • 1. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
    Modi NB; Eppler S; Breed J; Cannon CP; Braunwald E; Love TW
    Thromb Haemost; 1998 Jan; 79(1):134-9. PubMed ID: 9459338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
    Cannon CP; McCabe CH; Gibson CM; Ghali M; Sequeira RF; McKendall GR; Breed J; Modi NB; Fox NL; Tracy RP; Love TW; Braunwald E
    Circulation; 1997 Jan; 95(2):351-6. PubMed ID: 9008448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
    Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
    Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
    Van de Werf F; Barron HV; Armstrong PW; Granger CB; Berioli S; Barbash G; Pehrsson K; Verheugt FW; Meyer J; Betriu A; Califf RM; Li X; Fox NL;
    Eur Heart J; 2001 Dec; 22(24):2253-61. PubMed ID: 11728145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
    Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
    J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
    Van de Werf F; Cannon CP; Luyten A; Houbracken K; McCabe CH; Berioli S; Bluhmki E; Sarelin H; Wang-Clow F; Fox NL; Braunwald E
    Am Heart J; 1999 May; 137(5):786-91. PubMed ID: 10220625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
    De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
    Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.
    Wang-Clow F; Fox NL; Cannon CP; Gibson CM; Berioli S; Bluhmki E; Danays T; Braunwald E; Van De Werf F; Stump DC
    Am Heart J; 2001 Jan; 141(1):33-40. PubMed ID: 11136484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
    Gibson CM; Cannon CP; Murphy SA; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Fox NL; Berioli S; Weaver WD; Van de Werf F; Braunwald E
    Am J Cardiol; 1999 Nov; 84(9):976-80. PubMed ID: 10569649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
    Al-Shwafi KA; de Meester A; Pirenne B; Col JJ
    Am Heart J; 2003 Feb; 145(2):217-25. PubMed ID: 12595837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A faster-acting and more potent form of tissue plasminogen activator.
    Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction].
    Liang F; Wang LZ; Hu DY; Shi XB; Wei JP; Zhao H; Wang L; Jia SQ; Wang HY; Liu RH; Chen YD; Lu YL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):514-7. PubMed ID: 19927632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
    Kostis JB; Dockens RC; Thadani U; Bethala V; Pepine C; Leimbach W; Vachharajani N; Raymond RH; Stouffer BC; Tay LK; Shyu WC; Liao WC
    Clin Pharmacokinet; 2002; 41(6):445-52. PubMed ID: 12074692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
    Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
    Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
    Tanswell P; Modi N; Combs D; Danays T
    Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).
    Gibson CM; Marble SJ
    Clin Cardiol; 2001 Sep; 24(9):577-84. PubMed ID: 11558838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial.
    Wang HB; Ji P; Zhao XS; Xu H; Yan XY; Yang Q; Yao C; Gao RL; Wu YF; Qiao SB
    BMJ Open; 2017 Sep; 7(9):e016838. PubMed ID: 28928186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
    Serebruany VL; Malinin AI; Callahan KP; Binbrek A; Van De Werf F; Alexander JH; Granger CB; Gurbel PA;
    Am Heart J; 2003 Apr; 145(4):636-42. PubMed ID: 12679759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.